WallStSmart

Health Catalyst Inc (HCAT)vsVeeva Systems Inc Class A (VEEV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Veeva Systems Inc Class A generates 1083% more annual revenue ($3.46B vs $292.25M). VEEV leads profitability with a 29.3% profit margin vs -90.6%. VEEV earns a higher WallStSmart Score of 66/100 (B-).

HCAT

Avoid

34

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -3.47

VEEV

Strong Buy

66

out of 100

Grade: B-

Growth: 8.7Profit: 8.0Value: 6.7Quality: 9.0
Piotroski: 4/9Altman Z: 4.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HCAT.

VEEVUndervalued (+41.2%)

Margin of Safety

+41.2%

Fair Value

$301.18

Current Price

$262.40

$38.78 discount

UndervaluedFair: $301.18Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCAT1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

VEEV6 strengths · Avg: 8.8/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.7810/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
29.3%9/10

Keeps 29 of every $100 in revenue as profit

Operating MarginProfitability
29.6%8/10

Strong operational efficiency at 29.6%

Revenue GrowthGrowth
17.6%8/10

17.6% revenue growth

EPS GrowthGrowth
39.5%8/10

Earnings expanding 39.5% YoY

Areas to Watch

HCAT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$127.18M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.693/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VEEV1 concerns · Avg: 2.0/10
P/E RatioValuation
43.4x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : HCAT

The strongest argument for HCAT centers on Price/Book.

Bull Case : VEEV

The strongest argument for VEEV centers on Debt/Equity, Altman Z-Score, Profit Margin. Profitability is solid with margins at 29.3% and operating margin at 29.6%. Revenue growth of 17.6% demonstrates continued momentum.

Bear Case : HCAT

The primary concerns for HCAT are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.69 is elevated, increasing financial risk.

Bear Case : VEEV

The primary concerns for VEEV are P/E Ratio. A P/E of 43.4x leaves little room for execution misses.

Key Dynamics to Monitor

HCAT profiles as a turnaround stock while VEEV is a growth play — different risk/reward profiles.

HCAT carries more volatility with a beta of 1.56 — expect wider price swings.

VEEV is growing revenue faster at 17.6% — sustainability is the question.

VEEV generates stronger free cash flow (231M), providing more financial flexibility.

Bottom Line

VEEV scores higher overall (66/100 vs 34/100), backed by strong 29.3% margins and 17.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Health Catalyst Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. The company is headquartered in South Jordan, Utah.

Visit Website →

Veeva Systems Inc Class A

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.

Visit Website →

Want to dig deeper into these stocks?